Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
March 24, 2022 16:05 ET
|
Celyad Oncology SA
Highlights Phase 1 IMMUNICY-1 trial demonstrated encouraging data to date for CYAD-211 including a good tolerability profile and evidence of clinical activity in relapsed/refractory multiple myeloma...
Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call
March 17, 2022 07:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
March 02, 2022 02:30 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 02, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...
Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial
February 28, 2022 02:30 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...
Celyad Oncology Announces February 2022 Conference Schedule
January 31, 2022 16:05 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Provides Outlook for 2022
January 10, 2022 01:00 ET
|
Celyad Oncology SA
KEYNOTE-B79 and IMMUNICY-1 clinical trials evaluating the Company’s allogeneic CAR T candidates, CYAD-101 and CYAD-211 respectively, expected to generate key data throughout 2022 Company’s proprietary...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
December 31, 2021 01:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 31, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces January 2022 Conference Schedule
December 22, 2021 01:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Transparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2 May 2007)
December 17, 2021 16:05 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial
December 16, 2021 01:00 ET
|
Celyad Oncology SA
KEYNOTE-B79 Phase 1b trial will evaluate CYAD-101 and KEYTRUDA® (pembrolizumab) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC)ASCO-GI conference abstract accepted...